Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins

Biomaterials

Volumn 33, Issue 30, 2012, Pages 7665-7675

  Whitmire, Rachel E ^a   Scott Wilson, D ^b   Singh, Ankur ^a   Levenston, Marc E ^c   Murthy, Niren ^d   García, Andrés J ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b Georgia Institute of Technology   (United States)

^c STANFORD UNIVERSITY   (United States)

^d University of California at Berkeley   (United States)

Author keywords

Block copolymer; Drug delivery; IL 1Ra; Nanoparticles; Osteoarthritis; RAFT polymerization

Indexed keywords

ANTI-INFLAMMATORY PROTEINS; CHEMICAL CONDITIONS; COPOLYMER PARTICLES; DEGENERATIVE CHANGES; DELIVERY VEHICLE; DRUG-LOADING EFFICIENCY; HYDROPHOBIC CHARACTER; IL-1RA; IN-VITRO; IN-VIVO IMAGING; INTERLEUKIN-1; NATURAL PROTEINS; OSTEOARTHRITIS; PARTICLE PROCESSING; PARTICLE SURFACE; PROMISING THERAPY; PROTEIN DELIVERY; PROTEIN THERAPEUTICS; RAFT POLYMERIZATION; RECEPTOR ANTAGONISTS; RETENTION TIME; SELF-ASSEMBLING; SUBMICRON SCALE; SYNOVIOCYTES;

BLOCK COPOLYMERS; DRUG DELIVERY; JOINTS (ANATOMY); LIVING POLYMERIZATION; NANOPARTICLES; RATS;

PROTEINS;

COPOLYMER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NANOPARTICLE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SYNOVIOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARTILAGE; CELL DEATH; CELL LINE; DRUG DELIVERY SYSTEMS; FEMALE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; JOINTS; MALE; MICE; NANOPARTICLES; PHENOTYPE; POLYMERS; RABBITS; RATS; SIGNAL TRANSDUCTION; STIFLE; TIME FACTORS;

RATTUS;

EID: 84864975267     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.101     Document Type: Article

References (50)

1. CDC Osteoarthritis 2011, Available from:. http://www.cdc.gov/arthritis/basics/osteoarthritis.htm.
2. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58:15-25.
3. Peyron J.G. Epidemiologic and etiologic approach of osteoarthritis. Semin Arthritis Rheum 1979, 8:288-306.
4. Hellio Le Graverand-Gastineau M.P. OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?. Osteoarthritis Cartilage 2009, 17:1393-1401.
5. Pelletier J.P., Martel-Pelletier J., Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001, 44:1237-1247.
6. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
7. Arner E.C., Tortorella M.D. Signal transduction through chondrocyte integrin receptors induces matrix metalloproteinase synthesis and synergizes with interleukin-1. Arthritis Rheum 1995, 38:1304-1314.
8. Blom A.B., van der Kraan P.M., van den Berg W.B. Cytokine targeting in osteoarthritis. Curr Drug Targets 2007, 8:283-292.
9. Haynes M.K., Hume E.L., Smith J.B. Phenotypic characterization of inflammatory cells from osteoarthritic synovium and synovial fluids. Clin Immunol 2002, 105:315-325.
10. Pratta M.A., Scherle P.A., Yang G., Liu R.Q., Newton R.C. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003, 48:119-133.
11. Chevalier X., Goupille P., Beaulieu A.D., Burch F.X., Bensen W.G., Conrozier T., et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352.
12. Evans C.H., Robbins P.D., Ghivizzani S.C., Wasko M.C., Tomaino M.M., Kang R., et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 2005, 102:8698-8703.
13. Frisbie D.D., Ghivizzani S.C., Robbins P.D., Evans C.H., McIlwraith C.W. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002, 9:12-20.
14. Joosten L.A., Helsen M.M., van de Loo F.A., van den Berg W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809.
15. Fernandes J., Tardif G., Martel-Pelletier J., Lascau-Coman V., Dupuis M., Moldovan F., et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999, 154:1159-1169.
16. Perman V. Clinical biochemistry of domestic animals 1980, Academic Press. 3rd ed.
17. Wang H.J., Yu C.L., Kishi H., Motoki K., Mao Z.B., Muraguchi A. Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer. Chin Med J (Engl) 2006, 119:1365-1373.
18. Bias P., Labrenz R., Rose P. Sustained-release dexamethasone palmitate-pharmacokinetics and efficacy in patients with activated inflammatory osteoarthritis of the knee. Clin Drug Investig 2001, 21:429-436.
19. Horisawa E., Hirota T., Kawazoe S., Yamada J., Yamamoto H., Takeuchi H., et al. Prolonged anti-inflammatory action of dl-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 2002, 19:403-410.
20. Larsen C., Ostergaard J., Larsen S.W., Jensen H., Jacobsen S., Lindegaard C., et al. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci 2008, 97:4622-4654.
21. Johnson B.A., Javors M.A., Roache J.D., Seneviratne C., Bergeson S.E., Ait-Daoud N., et al. Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:209-216.
22. Lee B., Shinohara K., Weinberg V., Gottschalk A.R., Pouliot J., Roach M., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67:1106-1112.
23. Giteau A., Venier-Julienne M.C., Aubert-Pouessel A., Benoit J.P. How to achieve sustained and complete protein release from PLGA-based microparticles?. Int J Pharm 2008, 350:14-26.
24. Lasic D.D., Papahadjopoulos D. Medical applications of liposomes 1998, Elsevier.
25. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007, 4:297-305.
26. Gaertner H.F., Offord R.E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug Chem 1996, 7:38-44.
27. Gao W., Liu W., Christensen T., Zalutsky M.R., Chilkoti A. In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc Natl Acad Sci U S A 2010, 107:16432-16437.
28. Yu P., Zhang G., Bi J., Lu X., Wang Y., Su Z. Facile purification of mono-PEGylated interleukin-1 receptor antagonist and its characterization with multi-angle laser light scattering. Process Biochem 2007, 42:971-977.
29. Allen K.D., Adams S.B., Setton L.A. Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model. Tissue Eng Part B Rev 2010, 16:81-92.
30. Shamji M.F., Betre H., Kraus V.B., Chen J., Chilkoti A., Pichika R., et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum 2007, 56:3650-3661.
31. Bezemer J.M., Radersma R., Grijpma D.W., Dijkstra P.J., van Blitterswijk C.A., Feijen J. Microspheres for protein delivery prepared from amphiphilic multiblock copolymers. 2. Modulation of release rate. J Control Release 2000, 67:249-260.
32. Brown K.E., Leong K., Huang C.H., Dalal R., Green G.D., Haimes H.B., et al. Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins to the joint. Arthritis Rheum 1998, 41:2185-2195.
33. Whitaker M.J., Hao J., Davies O.R., Serhatkulu G., Stolnik-Trenkic S., Howdle S.M., et al. The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J Control Release 2005, 101:85-92.
34. Wen Z.Q., Cao X., Vance A. Conformation and side chains environments of recombinant human interleukin-1 receptor antagonist (rh-IL-1ra) probed by raman, raman optical activity, and UV-resonance Raman spectroscopy. J Pharm Sci 2008, 97:2228-2241.
35. Georgescu H.I., Mendelow D., Evans C.H. HIG-82: an established cell line from rabbit periarticular soft tissue, which retains the " activatable" phenotype. In Vitro Cell Dev Biol 1988, 24:1015-1022.
36. Kurz B., Steinhagen J., Schunke M. Articular chondrocytes and synoviocytes in a co-culture system: influence on reactive oxygen species-induced cytotoxicity and lipid peroxidation. Cell Tissue Res 1999, 296:555-563.
37. Smeets R.L., Joosten L.A., Arntz O.J., Bennink M.B., Takahashi N., Carlsen H., et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum 2005, 52:2202-2211.
38. Palmer A.W., Guldberg R.E., Levenston M.E. Analysis of cartilage matrix fixed charge density and three-dimensional morphology via contrast-enhanced microcomputed tomography. Proc Natl Acad Sci U S A 2006, 103:19255-19260.
39. Piscaer T.M., van Osch G.J., Verhaar J.A., Weinans H. Imaging of experimental osteoarthritis in small animal models. Biorheology 2008, 45:355-364.
40. Xie L., Lin A.S., Guldberg R.E., Levenston M.E. Nondestructive assessment of sGAG content and distribution in normal and degraded rat articular cartilage via EPIC-microCT. Osteoarthritis Cartilage 2010, 18:65-72.
41. Stenzel M.H. RAFT polymerization: an avenue to functional polymeric micelles for drug delivery. Chem Commun (Camb) 2008, 3486-3503.
42. Kracht M., Weber A., Wasiliew P. Interleukin 1 (IL-1) pathway. science signaling 2010, AAAS, Washington, D.C, p. The canonical IL-1 signaling pathway, as compiled by Science Signaling.
43. Boerckel J.D., Kolambkar Y.M., Dupont K.M., Uhrig B.A., Phelps E.A., Stevens H.Y., et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 2011, 32:5241-5251.
44. Phelps E.A., Landazuri N., Thule P.M., Taylor W.R., Garcia A.J. Bioartificial matrices for therapeutic vascularization. Proc Natl Acad Sci U S A 2010, 107:3323-3328.
45. Singh A., Nie H., Ghosn B., Qin H., Kwak L.W., Roy K. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol Ther 2008, 16:2011-2021.
46. Fischer D., Bieber T., Li Y., Elsasser H.P., Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999, 16:1273-1279.
47. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
48. Rothenfluh D.A., Bermudez H., O'Neil C.P., Hubbell J.A. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater 2008, 7:248-254.
49. Zille H., Paquet J., Henrionnet C., Scala-Bertola J., Leonard M., Six J.L., et al. Evaluation of intra-articular delivery of hyaluronic acid functionalized biopolymeric nanoparticles in healthy rat knees. Biomed Mater Eng 2010, 20:235-242.
50. Betre H., Liu W., Zalutsky M.R., Chilkoti A., Kraus V.B., Setton L.A. A thermally responsive biopolymer for intra-articular drug delivery. J Control Release 2006, 115:175-182.